o	Vaccibody and Adaptive Biotechnologies have entered into an exclusive
agreement for use of Adaptive's validated SARS-CoV-2 T cell epitopes 

o	Vaccibody will use a selected set of these SARS-CoV-2 T cell epitopes in its
second-generation SARS-CoV-2 vaccine trial, planned for Q4 2021

o	Vaccibody has the ambition to develop a T cell vaccine that may help address
the threat from future variants of concern by providing a more complete viral
protection, long-term immunity and viral clearance compared to first generation
vaccines  

o	Vaccibody to host a webcast on July 12, 2021 at 4 p.m. CET / 10 a.m. EDT. Link
at www.vaccibody.com/financial-reports-and-presentations 


Oslo, Norway, July 12, 2021 - Vaccibody AS (Euronext Growth (Oslo): VACC), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, announced today that it has
entered into an exclusive license agreement with Adaptive Biotechnologies
Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims
to translate the genetics of the adaptive immune system into clinical products
to diagnose and treat disease, to use a broad selection of virus-specific T cell
epitopes identified by Adaptive for Vaccibody to design and develop novel
SARS-CoV-2 vaccines. 

Vaccibody's development strategy for its second-generation SARS-CoV-2 vaccine is
designed to respond to the emerging threats of evolving variants with reduced
sensitivity to first generation vaccines that were developed using the 2020
prototype spike protein. The 2-armed strategy aims to develop two candidates for
the broad population. First, a vaccine candidate encoding the receptor binding
domain (RBD) derived from the South African beta variant of concern. And second,
a T cell based vaccine candidate, encoding multiple validated immunodominant,
conserved Adaptive-identified T-cell epitopes spanning multiple antigens across
the SARS-CoV-2 genome.

"To date, SARS-CoV-2 has resulted in the death of over 4 million people globally
and we are facing a tremendous threat from emerging variants of concern. We are
very excited to have access to Adaptive's T cell epitopes for our use in
developing second-generation SARS-CoV-2 vaccines to specifically address current
and future variants of concern. Vaccibody has exclusively licensed validated
SARS-CoV-2 T-cell epitopes for use in the design and development of our T-cell
vaccine candidates, including the candidate in our previously announced clinical
trial" said Agnete B. Fredriksen, Chief Innovation and Strategy Officer of
Vaccibody. 

Adaptive has mapped the T cell immune response using more than 6,500 samples
from patients impacted by COVID-19. Adaptive used its immune medicine platform,
leveraging its proprietary antigen mapping and deep sequencing capabilities, to
identify naturally processed and presented T-cell epitopes to SARS-CoV-2
antigens. Adaptive's T-cell epitopes will be used by Vaccibody in its modular
vaccine technology platform to target specific SARS-CoV-2 antigens to antigen
presenting cells.

Michael Engsig, Chief Executive Officer of Vaccibody continued, "Our aim is to
design and develop novel second-generation COVID-19 vaccines using Vaccibody's
unique modular vaccine technology platform and Adaptive's functionally
validated, immunodominant T-cell epitopes."

"The SARS-COV-2 virus' ability to rapidly mutate can impact the efficacy of many
first-generation vaccines. Adaptive's unique ability to read and access the
immune system enables us to identify and validate SARS-COV-2 T-cell epitopes
from convalescent COVID-19 individuals. We are excited to combine the strength
of validated T-cell epitopes, identified using our immune medicine platform,
with Vaccibody's innovative vaccine technology in fighting the pandemic," added
Harlan Robins, Chief Scientific Officer and co-founder of Adaptive
Biotechnologies. 

Mikkel W. Pedersen, Ph.D., Chief Scientific Officer of Vaccibody continued, "We
are thrilled to work with Adaptive Biotechnologies to accurately identify
immunogenic and conserved T-cell epitopes. Adaptive's epitopes have enabled us
to create a multivalent SARS-CoV-2 T-cell vaccine that may provide more complete
viral protection, long-term immunity and viral clearance compared to first
generation vaccines. Our T-cell candidate may have both prophylactic and
therapeutic potential and may also fit the profile of a universal SARS-CoV-2
vaccine booster for individuals previously vaccinated with Spike based
vaccines." 

Vaccibody has demonstrated that the SARS-CoV-2 vaccine candidate that
incorporates Adaptive's T-cell epitopes induces a rapid, strong and broad T-cell
response after administration of a single dose in a humanized preclinical model.

Under the terms of the license agreement, Adaptive has provided certain selected
T-cell epitopes for exclusive use in Vaccibody's next-generation SARS-CoV-2
vaccines. Vaccibody will be responsible for further development of the potential
T-cell SARS-CoV-2 vaccine candidates. Financial terms of this agreement will not
be disclosed.

The phase 1/2 trial is currently in the planning phase. The CTA (Clinical Trial
Application) is expected to be submitted in Q3 2021 and initiation is planned
for Q4 2021. The clinical trial will be conducted in Norway. Please also refer
to Vaccibody's announcement on June 29, 2021 about the clinical trial. 

Webcast 
Michael Engsig, Chief Executive Officer of Vaccibody, and other members of
Vaccibody's management team will host a webcast on July 12, 2021 at 4 p.m. CET /
10 a.m. EDT. Harlan Robins, Chief Scientific Officer of Adaptive
Biotechnologies, will also join them to discuss how Adaptive identified the T
cell epitopes that Vaccibody will use in its second generation COVID-19 vaccine
using its proprietary immune medicine platform. A presentation will be available
on Vaccibody's website, www.vaccibody.com/financial-reports-and-presentations,
before the webcast.


About Vaccibody 
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment of cancer and infectious diseases.
Vaccibody's vaccine technology specifically targets antigens to Antigen
Presenting Cells, which are essential for inducing rapid, strong and
long-lasting antigen-specific immune responses and elicit efficacious clinical
responses. Its lead product candidates include VB10.NEO, a cancer neoantigen
vaccine, which is exclusively outlicensed to Genentech and is in phase I/IIa
clinical trial for the treatment of melanoma, lung-, head and neck, renal-, and
bladder cancer